An observational study in Diabetes Mellitus, sponsored by MDCECRO LLC. Enrolling by invitation at 1 site in Latvia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by MDCECRO LLC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Diabetes Mellitus with a site in Latvia — 4 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · Latvia.
Among the 26 studies in Diabetes Mellitus with a site in Latvia, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 26th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →4 of the 26 studies in Diabetes Mellitus with a site in Latvia are open now. Recruiting first, the newest first:
Duk-Woo Park, MD · Sites in Latvia, United States, Australia and 11 more countries
Ages 20+
Pauls Stradins Clinical University Hospital · Sites in Latvia
Ages 25–80
Rigshospitalet, Denmark · Sites in Latvia, Argentina, Austria and 33 more countries
Ages 16+
A study can be open while its sites in Latvia have not opened yet or have stopped. Only those recruiting at a site in Latvia →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is below the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 711 across the 21 interventional studies, 782 across the 4 observational. Of the 21 that completed or were terminated, 16 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 26 have an industry lead sponsor. The 10 most frequent:
MDCECRO LLC is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
MDCECRO LLC has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
1 of the studies in Diabetes Mellitus with a site in Latvia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06846138Pauls Stradins Clinical University HospitalEnhancing the Efficacy and Tolerability of Metformin by add-on Polyherbal Formulation: a Gut Microbiome Study | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Diabetes Mellitus with a site in Latvia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Post market Clinical follow-up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in patients with Type 1 and Type 2 Diabetes Mellitus
To re-assess the benefits of CT3 series CGM and the risks of skin abnormalities, hypoglycaemia, hyperglycaemia so as to improve CT3 series CGM continuously.
Patients diagnosed with type 1 or 2 diabetes mellitus
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1.Those who have broken, scarred, red, swollen, or infected skin on the upper arms or abdomen.
2.Those who are allergic to alcohol disinfectants or medical adhesive tapes. 3.Those who have hematologic diseases that affect coagulation function or have been diagnosed with a bleeding tendency.
4.Those who have anemia or abnormal hematocrit. 5.Pregnant and lactating women. 6.Psychiatric abnormalities, cognitive and communication disorders, or highly stressed and uncooperative.
7.Those with subcutaneous edema at the wearing site. 8. Those who plan to undergo magnetic resonance imaging (MRI), computed tomography (CT), or X-ray examination within 14 days of wearing.
9. Those who have participated in clinical trials of drugs or devices within 1 month.
10.Those who are considered by the investigator to be inappropriate to participate in this PMCF study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The CT3 Series CGM System is a real-time, continuous glucose monitoring device indicated for the management of diabetes in adults (age≥18 years). Interpretation of the CT3 Series CGM System results should be based on the glucose trends and several sequential readings over time. The CT3 Series CGM System also aids in the detection of episodes of hyperglycaemia and hypoglycaemia. It is intended for single-patient use. It is intended to replace fingerstick blood glucose testing for diabetes treatment decisions unless otherwise indicated
This PMCF study (Version V2.0) uses a strong evaluation plan, with methods and timing carefully matched to the study's rules. It includes 72 patients
The Continuous Glucose Monitoring (CGM) is done for 14 days for each person. During this time, glucose readings are collected every three minutes in real-time Self-Monitoring of Blood Glucose (SMBG) involves using fingerstick tests to check glucose levels. Important measurements-like Time in Range (TIR), Time Above Range (TAR), Time Below Range (TBR), and error grid analysis-are taken at specific times, including at the beginning and on certain follow-up days. These timings help collect key data to check how well the device works in the short term and how it affects glucose control over the full monitoring period.
Time frame: 14 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Sep 2025, 3 months after the start.
Of 534 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 159. This study's planned 3 months is below that.
Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MDCECRO LLC